Shannon N. Westin, MD, MPH, discusses challenges with precision medicine in endometrial cancer.
Shannon N. Westin, MD, MPH, clinical investigator and director of Early Drug Development and Phase I Trials in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, discusses challenges with precision medicine in endometrial cancer.
Despite encouraging data with combination regimens such as lenvatinib (Lenvima) and pembrolizumab (Keytruda), toxicity remains a challenge, says Westin.
However, this does not mean that chemotherapy is the better alternative, she adds.
Precision medicine shows promise in the endometrial cancer space and research efforts are aimed at developing strategies to mitigate or prevent treatment-related adverse effects (AEs), Westin says.
Often, patients who experience AEs may want to stop treatment, even if the regimen is working. Finding a way to mitigate AEs will help patients remain on effective therapies, Westin concludes.